Suppr超能文献

后颅窝 A 组(PFA)室管膜瘤中的分子异质性和 CXorf67 改变。

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.

机构信息

Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120, Heidelberg, Germany.

Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

出版信息

Acta Neuropathol. 2018 Aug;136(2):211-226. doi: 10.1007/s00401-018-1877-0. Epub 2018 Jun 16.

Abstract

Of nine ependymoma molecular groups detected by DNA methylation profiling, the posterior fossa type A (PFA) is most prevalent. We used DNA methylation profiling to look for further molecular heterogeneity among 675 PFA ependymomas. Two major subgroups, PFA-1 and PFA-2, and nine minor subtypes were discovered. Transcriptome profiling suggested a distinct histogenesis for PFA-1 and PFA-2, but their clinical parameters were similar. In contrast, PFA subtypes differed with respect to age at diagnosis, gender ratio, outcome, and frequencies of genetic alterations. One subtype, PFA-1c, was enriched for 1q gain and had a relatively poor outcome, while patients with PFA-2c ependymomas showed an overall survival at 5 years of > 90%. Unlike other ependymomas, PFA-2c tumors express high levels of OTX2, a potential biomarker for this ependymoma subtype with a good prognosis. We also discovered recurrent mutations among PFA ependymomas. H3 K27M mutations were present in 4.2%, occurring only in PFA-1 tumors, and missense mutations in an uncharacterized gene, CXorf67, were found in 9.4% of PFA ependymomas, but not in other groups. We detected high levels of wildtype or mutant CXorf67 expression in all PFA subtypes except PFA-1f, which is enriched for H3 K27M mutations. PFA ependymomas are characterized by lack of H3 K27 trimethylation (H3 K27-me3), and we tested the hypothesis that CXorf67 binds to PRC2 and can modulate levels of H3 K27-me3. Immunoprecipitation/mass spectrometry detected EZH2, SUZ12, and EED, core components of the PRC2 complex, bound to CXorf67 in the Daoy cell line, which shows high levels of CXorf67 and no expression of H3 K27-me3. Enforced reduction of CXorf67 in Daoy cells restored H3 K27-me3 levels, while enforced expression of CXorf67 in HEK293T and neural stem cells reduced H3 K27-me3 levels. Our data suggest that heterogeneity among PFA ependymomas could have clinicopathologic utility and that CXorf67 may have a functional role in these tumors.

摘要

在通过 DNA 甲基化分析检测到的 9 个室管膜瘤分子群中,后颅窝型 A(PFA)最为常见。我们使用 DNA 甲基化分析来寻找 675 例 PFA 室管膜瘤中进一步的分子异质性。发现了两个主要亚群,PFA-1 和 PFA-2,以及 9 个次要亚型。转录组分析表明 PFA-1 和 PFA-2 具有明显不同的组织发生,但它们的临床参数相似。相比之下,PFA 亚型在诊断时的年龄、性别比例、预后以及遗传改变的频率上存在差异。一个亚型 PFA-1c 富含 1q 增益,预后相对较差,而 PFA-2c 室管膜瘤患者的 5 年总生存率>90%。与其他室管膜瘤不同,PFA-2c 肿瘤表达高水平的 OTX2,这是一种预后良好的这种室管膜瘤亚型的潜在生物标志物。我们还在 PFA 室管膜瘤中发现了复发性突变。H3 K27M 突变存在于 4.2%,仅发生在 PFA-1 肿瘤中,而未表征基因 CXorf67 的错义突变存在于 9.4%的 PFA 室管膜瘤中,但不存在于其他组中。我们在除 PFA-1f 以外的所有 PFA 亚型中均检测到高水平的野生型或突变型 CXorf67 表达,而 PFA-1f 富含 H3 K27M 突变。PFA 室管膜瘤的特征是缺乏 H3 K27 三甲基化(H3 K27-me3),我们测试了 CXorf67 结合 PRC2 并调节 H3 K27-me3 水平的假设。免疫沉淀/质谱检测到 EZH2、SUZ12 和 EED,PRC2 复合物的核心成分,与表达高水平 CXorf67 且不表达 H3 K27-me3 的 Daoy 细胞系中的 CXorf67 结合。在 Daoy 细胞中强制降低 CXorf67 水平可恢复 H3 K27-me3 水平,而在 HEK293T 和神经干细胞中强制表达 CXorf67 可降低 H3 K27-me3 水平。我们的数据表明,PFA 室管膜瘤的异质性可能具有临床病理效用,而 CXorf67 可能在这些肿瘤中具有功能作用。

相似文献

1
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Acta Neuropathol. 2018 Aug;136(2):211-226. doi: 10.1007/s00401-018-1877-0. Epub 2018 Jun 16.
3
Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Acta Neuropathol Commun. 2022 Sep 14;10(1):137. doi: 10.1186/s40478-022-01442-4.
5
Heterogeneity within the PF-EPN-B ependymoma subgroup.
Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.
6
Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
Cancer Cell. 2020 Dec 14;38(6):844-856.e7. doi: 10.1016/j.ccell.2020.10.009. Epub 2020 Nov 12.
7
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Nat Commun. 2019 May 13;10(1):2146. doi: 10.1038/s41467-019-09981-6.
8
H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
Mol Cell. 2020 Nov 19;80(4):726-735.e7. doi: 10.1016/j.molcel.2020.09.028. Epub 2020 Oct 12.
9
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Acta Neuropathol. 2021 Jun;141(6):959-970. doi: 10.1007/s00401-021-02300-8. Epub 2021 Mar 23.

引用本文的文献

1
Aberrant EZHIP expression drives tumorigenesis in osteosarcoma.
Nat Commun. 2025 Jul 22;16(1):6752. doi: 10.1038/s41467-025-61558-8.
2
Epigenetic modifications and their roles in pediatric brain tumor formation: emerging insights from chromatin dysregulation.
Front Oncol. 2025 Jun 17;15:1569548. doi: 10.3389/fonc.2025.1569548. eCollection 2025.
3
Aberrant histone modifications in pediatric brain tumors.
Front Oncol. 2025 Jun 10;15:1587157. doi: 10.3389/fonc.2025.1587157. eCollection 2025.
4
Optimizing outcomes in intracranial ependymoma: a contemporary review.
Front Oncol. 2025 Jun 10;15:1617169. doi: 10.3389/fonc.2025.1617169. eCollection 2025.
5
A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma.
Mol Cell. 2025 Jun 5;85(11):2110-2127.e7. doi: 10.1016/j.molcel.2025.04.026. Epub 2025 May 21.
6
The immunopeptidomic landscape of ependymomas provides actionable antigens for T-cell-based immunotherapy.
Neurooncol Adv. 2025 Jan 16;7(1):vdae226. doi: 10.1093/noajnl/vdae226. eCollection 2025 Jan-Dec.
8
Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth.
Neuro Oncol. 2025 Jul 30;27(6):1597-1610. doi: 10.1093/neuonc/noaf029.
9
Advances in molecular prognostication and treatments in ependymoma.
J Neurooncol. 2025 Apr;172(2):317-326. doi: 10.1007/s11060-024-04923-9. Epub 2025 Jan 6.
10
DNA methylation shapes the Polycomb landscape during the exit from naive pluripotency.
Nat Struct Mol Biol. 2025 Feb;32(2):346-357. doi: 10.1038/s41594-024-01405-4. Epub 2024 Oct 24.

本文引用的文献

1
DNA methylation-based classification of central nervous system tumours.
Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.
2
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
Nature. 2018 Jan 4;553(7686):101-105. doi: 10.1038/nature25169. Epub 2017 Dec 20.
4
H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
Childs Nerv Syst. 2017 Jul;33(7):1047-1051. doi: 10.1007/s00381-017-3481-3. Epub 2017 Jun 16.
5
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Nat Med. 2017 Apr;23(4):493-500. doi: 10.1038/nm.4296. Epub 2017 Feb 27.
6
OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma.
Cancer Discov. 2017 Mar;7(3):288-301. doi: 10.1158/2159-8290.CD-16-0844. Epub 2017 Feb 17.
7
Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Sci Transl Med. 2016 Nov 23;8(366):366ra161. doi: 10.1126/scitranslmed.aah6904.
8
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.
Acta Neuropathol. 2017 Jan;133(1):5-12. doi: 10.1007/s00401-016-1643-0. Epub 2016 Nov 17.
10
Evidence of H3 K27M mutations in posterior fossa ependymomas.
Acta Neuropathol. 2016 Oct;132(4):635-7. doi: 10.1007/s00401-016-1608-3. Epub 2016 Aug 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验